Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Andrew L LaccettiBenjamin GarmezyLianchun XiaoMinas P EconomidesAradhana VenkatesanJianjun GaoEric JonaschPaul CornAmado Zurita-SaavedraLandon C BrownChester KaoEmily N KinseyRajan T GuptaMichael R HarrisonAndrew J ArmstrongDaniel J GeorgeNizar TannirPavlos MsaouelAmishi ShahTian ZhangMatthew T CampbellPublished in: Cancer medicine (2021)
To our knowledge, this is the first case series reporting off-label use of combination TKI-IO for mRCC. TKI-IO combinations, particularly N+P and N+C, are well tolerated and efficacious. Although further prospective research is essential, slow disease progression on IO or TKI monotherapy may be safely controlled with addition of either TKI or IO.